Children's Oncology Group's 2023 blueprint for research: Renal tumors
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30586 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von James I Geller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Rhabdoid Tumor, Sarcoma, Clear Cell, Kidney Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Every year, approximately 600 infants, children, and adolescents are diagnosed with renal cancer in the United States. In addition to Wilms tumor (WT), which accounts for about 80% of all pediatric renal cancers, clear cell sarcoma of the kidney, renal cell carcinoma, malignant rhabdoid tumor, as well as more rare cancers (other sarcomas, rare carcinomas, lymphoma) and benign tumors can originate within the kidney. WT itself can be divided into favorable histology (FHWT), with a 5‐year overall survival (OS) exceeding 90%, and anaplastic histology, with 4‐year OS of 73.7%. Outcomes of the other pediatric renal cancers include clear cell sarcoma (5‐year OS: 90%), malignant rhabdoid tumor (5‐year OS: 10% for stages 3 and 4), and renal cell carcinoma (4‐year OS: 84.8%). Recent clinical trials have identified novel biological prognostic markers for FHWT, and a series of Children's Oncology Group (COG) trials have demonstrated improving outcomes with therapy modification, and opportunities for further care refinement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia, USA.
- Hematology and Oncology, Cook Children's Medical Center, Fort Worth, Texas, USA.
- Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Division of Pediatric Surgery, Department of Surgery, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio, USA.
- Department of Surgery, Division of Urology and the Surgical Oncology Program at Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.
ORCID-Profile: James I Geller, Kelly L Vallance, Jennifer H Aldrink
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Geller, J. I., Hong, A. L., Vallance, K. L., Evageliou, N., Aldrink, J. H., Cost, N. G., Treece, A. L., Renfro, L. A., Mullen, E. A., & COG Renal Tumor Committee (2023). Children's Oncology Group's 2023 blueprint for research: Renal tumors. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30586
Vancouver
Geller JI, Hong AL, Vallance KL, Evageliou N, Aldrink JH, Cost NG, et al. Children's Oncology Group's 2023 blueprint for research: Renal tumors. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30586
BibTeX
@article{Geller2023,
author = {Geller, James I and Hong, Andrew L and Vallance, Kelly L and Evageliou, Nick and Aldrink, Jennifer H and Cost, Nicholas G and Treece, Amy L and Renfro, Lindsay A and Mullen, Elizabeth A and COG Renal Tumor Committee, COG Renal Tumor Committee},
title = {Children's Oncology Group's 2023 blueprint for research: Renal tumors},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30586}
}
EUVIMED